Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT^® trial

References

• Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med.176, 532–555 (2007).
   PubMed Web of Science ®Google Scholar
• Celli B, Roger S. Mitchell lecture: chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc. Am. Thorac. Soc.3, 461–465 (2006).
   PubMedGoogle Scholar
• Mannino DM, Homa DM, Akinbami LJ et al. Chronic obstructive pulmonary disease surveillance – United States. 1971–2000. Respir. Care47, 1184–1199 (2002).
   PubMedGoogle Scholar
• Coultas DB, Mapel D, Gagnon R et al. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am. J. Respir. Crit. Care Med.164, 373–377 (2001).
   Google Scholar
• Lopez AD, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J.27, 397–412 (2006).
   PubMed Web of Science ®Google Scholar
• Stevenson NJ, Walker PP, Costello RW et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.172, 1510–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW; GLOBE study group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax58, 589–593 (2003).
   PubMed Web of Science ®Google Scholar
• Gunen H, Hacievliyagil SS, Kosar F et al. Factors affecting survival of hospitalised patients with COPD. Eur. Respir. J.26, 234–241 (2005).
   PubMed Web of Science ®Google Scholar
• Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.164, 358–364 (2001).
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax57, 847–852 (2002).
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J.19, 217–224 (2002).
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur. Respir. J.19, 209–216 (2002).
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax58, 399–404 (2003).
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann. Intern. Med.143, 317–326 (2005).
   PubMed Web of Science ®Google Scholar
• Dusser D, Bravo M-L, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J.27, 547–555 (2006).
   PubMed Web of Science ®Google Scholar
• Powrie DJ, Wilkinson TMA, Donaldson GC et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Respir. J.30, 472–478 (2007).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Tashkin DP, Menjoge S et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Therapeutics18, 75–81 (2005).
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: The Uplift Trial. COPD1, 303–312 (2004).
   PubMedGoogle Scholar
• Anthonisen NR, Connett JE, Kiley JP et al. Effects of smoking intervention and the use of an anticholinergic bronchodlator on the rate of deline in FEV1. The Lung Health Study. JAMA272, 1497–1505 (1994).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S et al. A four-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.359, 1543–1554 (2008).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Standardization of spirometry – 1994 update. Am. J. Respir. Crit. Care Med.152, 1107–1136 (1995).
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM et al. A self-complete measure of health status for chronic airflow limitation: the St. George’s Respiratory Questionnaire. Am. Rev. Respir. Dis.145, 1321–1327 (1992).
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Kesten S et al. Effects of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet374, 1171–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br. Med. J.1(6077), 1645–1648 (1977).
   PubMed Web of Science ®Google Scholar
• Scanlon PD, Connett JE, Waller L et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: The Lung Health Study. Am. J. Respir. Crit. Care Med.161, 381–390 (2000).
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med.166, 675–679 (2002).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J.103, 963–974 (2009).
   Google Scholar
• Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur. Respir. J.19, 398–404 (2002).
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S et al. Mortality in the 4 year trial of tiotropium (UPLIFT) in patients with COPD. Am. J. Respir. Crit. Care Med.180, 948–955 (2009).
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA300, 1439–1450 (2008).
   PubMed Web of Science ®Google Scholar
• Kesten S, Celli B, Decramer M et al. Tiotropium handihaler in the treatment of COPD: a review of safety. Int. J. COPD4, 397–409 (2009).
   Google Scholar
• Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest137, 20–30 (2010).
   PubMed Web of Science ®Google Scholar
• Celli BR, NacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J.23, 932–946 (2004).
   PubMed Web of Science ®Google Scholar
• Lee TA, Wilke C, Joo M et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch. Intern. Med.169, 1403–1410 (2009).
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J et al. Cardiovascular morbidity and the use of inhaled bronchodilators. Int. J. COPD3, 1–7 (2008).
   Google Scholar
• Halpin DMG, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD6, 211–225 (2009).
   PubMedGoogle Scholar
• Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med.178, 332–338 (2008).
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. Lung Health Study II. N. Engl. J. Med.343, 1902–1909 (2000).
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PMA, Jones PW et al. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ320, 1297–1305 (2000).
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl C, Laitinen LA et al.; for the European Respiratory Society study on chronic obstructive pulmonary disease. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med.340, 1948–1953 (1999).
   PubMed Web of Science ®Google Scholar
• Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study BRONCUS): a randomised placebo-controlled trial. Lancet365, 1552–1560 (2005).
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.356, 775–789 (2007).
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Fabbri LM. Prevention of death in COPD (letter). N. Engl. J. Med.356, 2211–2212 (2007).
   PubMed Web of Science ®Google Scholar
• Hanania NA, Sharafkhaneh A, Celli B et al. Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium. Eur. Respir. J.34, 777S (2009).
   Google Scholar
• Tashkin DP, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without acute bronchodilator responses. Chest123, 1441–1449 (2003).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J.34, 757–769 (2009).
   PubMed Web of Science ®Google Scholar
• Fitzgerald MR, Fox JC. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov. Today12, 472–478 (2007).
   PubMed Web of Science ®Google Scholar
• Hochrainer D, Holz H, Kreher C et al. Comparison if the aerosol velocity and spray duration of Respimat® Soft Mist™ inhaler and pressurized metered dose inhalers. J. Aerosol Med.18, 273–282 (2005).
   PubMedGoogle Scholar
• Voshaar T, Lapidus R, Maleki-Yazdi et al. A randomized study of tiotropium Respimat® Soft Mist Inhaler™ Respimat™ Soft Mist™ inhaler vs ipratropium pMDI in COPD. Respir. Med.102, 32–41 (2008).
   PubMed Web of Science ®Google Scholar
• Seifart C, Vogelmeier C. Emerging drugs in chronic obstructive pulmonary disease. Expert Opin. Emerg. Drugs14, 181–194 (2009).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Piccioll S, Matera MG. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Expert Opin. Pharmacother.11, 441–449 (2010).
   PubMed Web of Science ®Google Scholar